Introduction p53 appears to play a central role in the cellular response to irradiation damage by activating an apoptotic or growth arrest pathway in proliferating cells (Maltzman and Czyzyk, 1984; Kastan et al., 1992; Kuerbitz et al., 1992; Hall et al., 1993; Lu and Lane, 1993; Zhan et al., 1993; Clarke et al., 1993; Lowe et al., 1993; Merritt et al., 1994; Yonish et al., 1991 ). The precise mechanism by which p53 is activated by cellular stress is of intense interest and may involve both increases in p53 protein level and in the specific activity of p53 by covalent modification. Although direct activation of the latent sequence-specific DNA binding activity of human ~53 can occur through ultraviolet (UV) light and serum-responsive signaling pathways in insect cell systems (Hupp and Lane, 1995) , upstream intracellular signaling pathways involved in the direct activation of the biochemical function of p53 in mammalian cells following irradiation have not been clearly delineated, nor have the actual enzymes activating p53 function in vivo been identified. Biochemical analysis of p53 has shown that it interacts with many proteins implicated in regulation of ~53 protein function, including protein kinases and phosphatases, heat shock proteins, and DNA binding proteins. The biochemical activity of p53 may also be regulated by interaction of the C-terminus with single stranded RNA or DNA (Oberosler et al., 1993; Bakalkin et al., 1994; Jayaraman and Prives, 1995) . The activity of ~53 most tightly linked to its tumor suppressor activity is the ability of the protein to bind to DNA sequence-specifically (Kern et al., 1992; El-Deiry et al., 1992) . Inactivating point mutations usually map within the active site for sequencespecific DNA binding or within the central core DNA binding domain (Cho et al., 1994; Halazonetis and Kandil, 1993; Bargonetti et al., 1993) . Thus, sequence-specific DNA binding is a biologically relevant function of ~53, and understanding its regulation may reveal mechanisms whereby the cell regulates a key damage-responsive pathway.
Biochemical analysis of the regulation of wild-type ~53 sequence-specific DNA binding has shown that the unphosphorylated tetramer has a cryptic sequence-specific DNA binding activity (Hupp et al., 1992) . This cryptic or latent state of ~53 depends upon a C-terminal negative regulatory domain, which locks the unphosphorylated tetramer in an inactive state. Phosphorylation of the C-terminal negative regulatory domain of latent ~53 by either protein kinase C or casein kinase II (Hupp and Lane, 1994b; Delphin and Baudier, 1994; Takenaka et al., 1995) or deletion of this regulatory domain (Hupp et al., 1992) , activates sequence-specific DNA binding. In addition, a monoclonal antibody or bacterial heat shock protein 70 (Hsp70), whose binding sites reside in the C-terminal negative regulatory domain, mimic the affects of protein kinases and activate latent ~53 through a concerted transition of subunits in the tetramer (Hupp and Lane, 1994a) . Thus, neutralization of this negative regulatory domain by covalent or noncovalent modification is an important stage in the activation of ~53.
To demonstrate directly that this activation pathway operates in mammalian cells, we show that the activation of p53 as a sequence-specific transcription factor following UV irradiation does not require increases in protein level and can be mimicked in vivo by the intranuclear microinjection of antibody directed to the C-terminal negative regulatory domain of ~53. In light of our results, we propose a model in which each C-terminal negative regulatory domain interacts with a motif in the core of the tetramer and must be displaced to permit the specific DNA binding activity of the protein. A prediction of this model, that small peptides derived from the C-terminal negative regulatory domain might interfere with this intra or intermolecular interaction and activate the DNA binding function of latent ~53, is confirmed. Definition of the molecular details of this control pathway that regulates the cellular response to irradiation damage suggests the possibility of rational design of low molecular mass modifiers of the ~53 response.
Results

UV-Induced Activation
of the Transcriptional Function of p53 Does Not Require an Increase in p53 Protein Levels: Support for a Model of p53 Activation by Posttranslational Modification The levels of ~53 protein rise dramatically in some cells and tissues exposed to DNA-damaging radiation (Maltzman and Czyzyk, 1984; Kastan et al., 1991; Hall et al., 1993; Midgley et al., 1995) . This rise in ~53 protein following irradiation is associated with enhanced transcription of p53-responsive genes (Lu and Lane, 1993; Zhan et al., 1993) . Although the mechanism by which p53 levels increase in the environment of the irradiated cell is not known, the increase in p53 protein concentration provides a simple explanation for the increase in transcription from p53-responsive genes. However, an alternate mechanism forthe regulation of p53-dependent transcription has been suggested by a series of biochemical studies on the regulation of the sequence-specific DNA binding function of ~53. These studies show that p53 can be produced in a biochemically latent state that can be activated for specific DNA binding after the modification of a C-terminal negative regulatory domain by distinct enzymes in vitro (Hupp and Lane, 1994b) . Furthermore, signaling pathways that respond to UV radiation or growth factors in serum can directly activate sequence-specific DNA binding function of p53 in cells (Hupp and Lane, 1995) . According to this model, then, covalent modification of ~53 without increase in protein level may be sufficient to activate the ~53 response following DNA damage in normal cells.
To test these two models, we used a wild-type p53 containing murine fibroblast cell line with a stably integrated p53-responsive (Ggalactosidase reporter gene. When these cells are exposed to intermediate doses of UV light (20 and 40 J/m") two events are observed: p53 levels rise, as judged by a sensitive enzyme-linked immunosorbent assay (ELISA) (Figure 1 A) , and expression of the P-galactosidase reporter gene is activated as determined by cell staining ( Figure 1B) . Notably, the dose-response curve shows that at lower doses of UV irradiation (10 J/mZ), p53-dependent transcription is activated without any detectable increase in p53 protein level ( Figures 1A and 1B) . These results imply that the specific activity of ~53 as a transcription factor can be altered by irradiation without increasing ~53 protein concentrations.
In addition, these results suggest that unirradiated fibroblasts contain a pool of latent p53 that can be activated by a factor in response to DNA damage. To establish the existence of this pool of latent p53 in unirradiated cells, we sought to activate it independent of DNA damage. The antibody PAb421 is a potent activator of the DNA binding function of latent ~53 in vitro, so we tested the capacity of the PAb421 antibody to activate p53-dependent transcription in vivo by microinjection. Cells were microiniected with control buffer (2i), the activating antibody PAb421 (2ii), or the inhibiting antibody PAb246 (2iii), incubated for 16 hr, and then stained for 6-galactosidase production as in Figure 1 used for these studies ( Figure  3A ). Peptide C, (C369-383), which harbors both the protein kinase C site and the while peptides C5-C12 contain an N-terminal biotin group linked to the amino acid sequence SGSG. The shaded amino acids depict high affinity amino acid contacts required for potent p53 activation, which is summarized on the left, from data in Figure 7 . (B) Incubation of latent ~53 tetramers with synthetic peptides derived from the C-terminal regulatory domain. p53 protein (50 nM) was assembled in activation reactions with a panel of synthetic peptides as follows. Lane 1, no peptide; lanes 2-4, 1, 10, and 100 uM peptide C; lanes 5-7, 1, 10, and 100 uM peptide C2; lanes 8-10, 1, 10, and 100 uM peptide Cs. After a 30 min incubation at 30°C, sequence-specific DNA binding was assayed at 0°C as indicated in the Experimental Procedures.
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activates ~53 at peptide concentrations of 100 FM ( Figure 3B , lanes 2-4 versus lane 1). Synthetic peptides Cp (C364-378, lanes 5-7), CJ (C374-388, lanes 8-10) or Cq (data not shown) at concentrations up to 100 PM do not activate p53 function, indicating that activation by peptide C, is highly specific. These results are consistent with the model whereby specific amino acid contacts between the regulatory site and a surface subdomain can be disrupted to give rise to the allosteric activation of ~53.
Synergistic
Activation of Latent p53 by Use of Casein Kinase II and a Synthetic Peptide Derived from the Negative Regulatory Domain The activation of the latent sequence-specific DNA binding function of ~53 seen with peptide C, is modest. We sought to find conditions where the effect was enhanced so that we could examine the specificity of the activating peptides in more detail. Specifically, we have taken advantage of the fact that, under specific conditions, stoichiometric 12 3 4 5 6 7 8 91011 B phosphorylation of wild-type ~53 can be uncoupled from its activation (see below, Figure 8 ).
The rate of p53 activation by casein kinase II was analyzed by using catalytic levels of recombinant casein kinase II (lo-fold lower molar equivalents); underthese reaction conditions, p53 becomes progressively more active from 2-10 min at 30°C ( Figure 4A , lanes l-5), despite the fact that stoichiometric phosphorylation has occurred within 30 s ( Figure 4B ). These results indicate that phosphorylation by recombinant casein kinase II is avery rapid step and that subsequent conformational changes leading to p53 activation are rate limiting.
Under these conditions, in which there is a lower level of ~53 activation, but stoichiometric phosphorylation of the protein, the subsequent addition of peptide C, at 0% dramatically stimulated ~53 sequence-specific DNA binding ( Figure 4A , lanes 7-l 1) to achieve a specific activity similar to PAb421-activated ~53 (data not shown). The N-terminal antibody DO-1 shifts the migration of this pro- (A) Synergistic activation of phospho-p53 with a synthetic peptide derived from the C-terminal regulatory domain. p53 (50 nM) was left unphosphorylated (lanes 1 and 6) or phosphorylated at 30°C with recombinant human casein kinase II (Hupp et al., 1993) , 2 ng for 1 min. After phosphorylation, the reactions were incubated further for 1, 2,5, and 10 min at 30%. Subsequently, peptide C, (20 FM) was added (lanes 6-l 1) during DNA binding at 0% and products were analyzed as indicated in the Experimental
Procedures. 
Activation of Latent ~53 by Use of DnaK and a Synthetic Peptide Derived from the Negative Regulatory Domain To gain further insight into the activation of ~53 by synthetic peptides, we investigated whether a prior modification of the C-terminal regulatory site of ~53 by a nonkinase activator could also give rise to synergistic activation by peptides. This second assay takes advantage of the facts first that the Escherichia coli Hsp70 protein (DnaK) can also interact with latent ~53 tetramers to unmask the cryptic sequence-specific DNA-binding activity efficiently in vitro (Hupp et al., 1992 (Hupp et al., , 1993 ; second, that DnaK targets the C-terminal negative regulatory domain at a site within peptide Cs (data not shown); and third, that activation of ~53 by DnaK can now be divided into two stages; a latent DnaK-p53 intermediate complex can be stably isolated at 0% (see below).
Activation of latent ~53 by DnaK requires an incubation at 30°C, as activation of ~53 does not occur when reactions are incubated at 0°C ( Figure 5 , lane 6). As DnaK does not activate ~53 at O%, the ability of peptide C, to synergize in concert with DnaK under these conditions was examined. Importantly, and in contrast with peptide CJ, the activating peptide C, does not bind to DnaK (data Figure 5 . Activation of Latent ~53 with Peptide C, and DnaK p53 protein (50 nM) was assembled in activation buffer with increasing amounts of peptide C, alone (lanes 1-5; 0 uM, 12 PM, 25 vM, 50 KM, and 100 PM, respectively) or with DnaK (2.8 vM) and increasing amounts of peptide C, (lanes 6-10; 0 PM, 12 PM, 25 PM, 50 PM, and 100 vM, respectively) at 0% for 30 min. After the addition of DNA binding buffer and radiolabeled DNA, products were analyzed as indicated in Experimental
Procedures.
not shown). As seen previously, a titration of peptide C,, in the absence of DnaK at O°C, gives rise to a modest activation of latent ~53 ( Figure 5 , lanes l-5). In contrast, a titration of peptide C,, in the presence of DnaK at 0% ( Figure 5 , lanes 7-10 versus lane 6), gives rise to a dramatic activation of latent ~53 with an apparent K, of peptide activation being 32 PM. The specific activity of DnaK-peptide-activated ~53 at 0% was identical to that of DnaK-activated ~53 at 30°C (data not shown). Alterations in the pH, ionic strength, or time of incubation does not lead to a DnaK-dependent activation of ~53 at 0% in the absence of peptide (data not shown).
Alanine Scan of the Activating Peptide Defines Specific Amino Acids Required to Activate Latent Forms of ~53 Truncation of the activating peptide defines endpoints required for activation of ~53. A panel of biotinylated peptides that contain N-terminal or C-terminal deletions of the activating peptide Cr (a biotinylated version of the activating peptide C,; see Figure 3 ) was used to define the end limits required for peptide activation with DnaK at 0%. A titration of peptide C7 activates p53 by using DnaK with an apparent K, of activation being 9 FM (Figure 6 ), which is approximately 4-fold lower than that obtained with the nonbiotinylated peptide C, in the presence of DnaK. Truncated derivatives of the full-length peptide, peptides CS and Cs, could also coactivate with DnaK, but the apparent K, of activation was slightly higher at 30 PM. However, further truncation from the N-terminus (peptide GO or CW) or from the C-terminus (peptide C,,) prevented peptide activation, thus defining N-and C-terminal endpoints required for high affinity activation of ~53.
A series of peptides with single alanine substitutions at every position from amino acids 369-383 was used to define critical amino acids within the full-length peptide that function in the activation of ~53 (Figure 7) . These results define a consensus polypeptide sequence that plays an essential role in the rate-limiting activation of ~53. Specifically, substitution of any of the positively charged amino acids (K370, K372, K373, R379, K381, or K382) with alanine dramatically reduces the ability of the 19 amino acid synthetic peptide to activate p53 potently. Sub- stitutions of the remaining nine amino acids with alanine are tolerated and do not dramatically reduce the apparent K, of activation. These results begin to define the exact molecular requirements and assay conditions to develop low molecular mass regulators of the p53 allosteric activation pathway.
A Rate-Limiting
Step in the Activation of ~53 Sequence-Specific Transcriptional Function In Vivo Prior to these studies, key chemical steps involved in directly activating p53 protein following DNA damage in mammalian cells have been undefined. However, the ability to activate the sequence-specific transcriptional function of wild-type p53 in vivo, by using a monoclonal antibody (PAb421) known to activate the specific DNA binding function of ~53 in vitro, underscores the rate-limiting role of this allosteric activation reaction in modulating the p53 pathway. These data establish the presence of a pool of latent ~53 that can be activated posttranslationally in normal cells and demonstrate that the activation of p53-responsive reporter genes can occur in the absence of other signals that might be mediated by DNA damage within the cells, i.e., direct effects on the template DNA. Indeed, a p53-dependent superinduction of ~21~'~' mRNA was observed upon serum stimulation of quiescent wildtype fibroblasts in the presenceof cycloheximide (Macleod et al., 1995) , suggesting that activation of p53 transcriptional function can occur in the absence of protein synthesis In addition, the fact that modification of ~53 in the C-terminal negative regulatory domain resulting in loss of the antibody PAb421 epitope (Milner, 1984; Ullrich et al., 1992; Hupp and Lane, 1995) or alternative splicing of mouse p53 mRNA resulting in removal of the negative regulatory domain occurs in tissue culture systems (Arai et al., 1986; Kulesz-Martin et al., 1994) indicates that modification of the negative regulatory domain can occur in vivo in the absence of DNA damage.
That activation of the transcriptional activity of ~53 can occur without an increase in p53 protein levels is consistent with the existence of distinct cellular signaling pathways capable of modulating theconversion between latent and activated forms of p53 (Hupp and Lane, 1995) . The results also explain how microinjection of antibodies to the C-terminus of ~53 can block cell cycle progression (Mercer et al., 1982 (Mercer et al., , 1984 Deppert et al., 1990) by virtue of activating the biochemical function of endogenous p53 protein. As such, determining the mechanism of ~53 activation may have future therapeutic relevance. Selective activation of wild-type p53 by agents that do not induce DNA damage may differentially alter the response of normal tissue as compared with that of p53-negative tumor cells to therapeutic agents toxic only to rapidly cycling tumor cells. On the other hand, one class of mutation in ~53 results in proteins that cannot be activated after phosphorylation, but can be activated in vitro by binding of the activating monoclonal antibody PAb421 (Hupp et al., 1993; Niewolik et al., 1995) . The latter study is notable, as almost one third of the mutant forms of p53 synthesized in human tumor cell lines can be activated in vitro by the binding of PAb421, suggesting that aconsiderable proportion of human tumors might respond to allosteric activators by rescuing their p53 response.
An Allosteric Model for the Activation of p53
The mechanism of p53 latency and the mechanism whereby the protein is activated after covalent modification are not known. In addition, neither the crystal structure of the full-length unphosphorylated p53 tetramer nor that of the phosphorylated tetramer are known, thus precluding predictions on the mechanisms of latency and activation. However, using synthetic peptides derived from the C-terminal negative regulatory domain of ~53, we have defined a small molecule that can activate latent p53 function, and this information has led to a specific biochemical model reflecting a possible mechanism of ~53 latency and a mechanism whereby phosphorylation alters polypeptide structure. The key elements of this model are that the C-terminal tails of p53 interact with the core of the molecule (Figure 8 ). This interaction locks the core into a conformation that is inactive for DNA binding. When this tail-core interaction is disrupted by covalent modification, noncovalent modification, or deletion, the core is then able to adopt the active form. Complete activation of ~53 is not accomplished effectively by synthetic polypeptides alone, suggesting that negative regulatory domain interactions are not easily disrupted. The stability of the negative regulatory domain interactions are also manifested in the ability to purify to homogeneity latent p53 tetramers by using three sequential chromatographic matrices (Hupp and Lane, 1994a); i.e., a spontaneous shift in equilibrium from the latent to activated state during purification would have reduced latent tetramer yield if ~53 negative regulatory domain-tetramer interactions were of low affinity and subject to destabilization. and a peptide-binding pocket within the tetramer. Deletion of the regulatory domain or its phosphorylation and subsequent incubation at high temperature (30%) disrupts regulatory domain interactions and converts the latent tetramer to an activated tetramer through aconcerted transition ofsubunits. Activation byposttranslational modification at the regulatory site can now be separated into two stages. The first step is a rapid event in which the regulatory domain is modified (i.e., by covalent modification), but the energy barrier required to disrupt the regulatory domain-tetramer interaction is not overcome. Activation of p53 p53 (indicated amounts) was added to 10 ~1 of activation buffer (10% glycerol, 1 .O mglml BSA, 0.05 M KCI, 0.1 mM EDTA, 5 mM DTT, 0.05% Triton X-100,10 mM MgCI,, 0.5 mM ATP [or 50 PM ATP when activated with protein kinases] and 25 mM HEPES [pH 7.6]), followed by incubation at 30°C for 30 min with indicated activating factor or peptide. Reactions were placed at O°C with 10 PI of a DNA binding buffer (20% glycerol, 1.0 mglml BSA, 0.05 M KCI, 0.1 mM EDTA, 5 mM DTT, 0.05% Triton X-100, 10 mM MgCI,, 0.5 mM ATP, 5 ng of radiolabeled consensus site oligonucleotide [Hupp et al., 19921) and 100 ng of supercoiled pBluescript competitor DNA. Reaction products were processed by using native gel electrophoresis as indicated previously (Hupp et al., 1992) .
DNA Transfections and UV Treatment RGCAFos
LacZ plasmid DNA (IO Kg) and DOR neo2 plasmid DNA (1 vg) were cotransfected into 5 x 1 O5 cells (B-galactosidase cells) by calcium phosphate precipitation followed by a 15% glycerol shock. The transfected cells were cultured in selection medium supplemented with 1 Kg/ml G418 (b-galactosidase cells) to select cells containing neo plasmid. Fourteen resistant cells were cloned by cloning ring and expanded.
The b-galactosidase activity was measured 12 hr after the cells were exposed to IO J/m* of UV to induce the endogenous wildtype ~53, and the most responsive clone was used to carry out further study. When cells had grown to 80% confluence, in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1 pglml G418, culture medium was removed, and the cells were exposed to UV in an XL-1500UV cross-linker (Spectronics Corporation). The energy of UV light delivered was precisely controlled by the cross-linker.
After exposure, the cells were grown in fresh culture medium for 16 hr before LacZ expression was determined. Cells were then washed with phosphate-buffered saline (PBS) and fixed with 2% formaldehyde, 0.2% glutaraldehyde in PBS for 5 min on ice. Cells were washed with PBS and overlaid with 0.25 mglml X-Gal in reaction mix (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium chloride in PBS). Cells were incubated at 37OC for 16 hr and b-galactosidase-positive cell numbers determined.
Murine p53 ELBA Levels of murine p53 were determined in a two-site immunoassay as follows. Falcon microtiter dish wells were coated with 50 PI of purified mouse monoclonal antibody PAb248 at 30 pglml in carbonate coating buffer for 8 hr at 4°C. The capture antibody was then removed and the plates blocked with 200 ~1 of 3% BSA in PBS overnight at 4°C. The plates were washed (1 x PBS, 2 x 0.1% NP-40 in PBS, 1 x PBS) and 50 ~1 of serially 2-fold-diluted cell extract added for 3 hr at 4OC. Cell extracts were prepared by lysis in ice-cold NET buffer (50 mM Tris-HCI [pH 8.01, 150 mM NaCI, 5 mM EDTA, 1% NP-40) containing 2 mM phenylmethylsulfonyl fluoride, for 30 min at 4°C. Debris was removed from the lysate by centrifugation at 14,000 rpm in a refrigerated Eppendorf centrifuge.
Cell lysates were removed, avoiding crosscontamination, and the plates washed as before. Captured murine p53 was detected by using 50 I.LI of the rabbit anti-p53 serum CM1 diluted 1:lOOO in 1% BSA in PBS for 2 hr at 4OC. The plates were washed, and 50 pl of horseradish peroxidase-conjugated swine antirabbit IgG diluted I:1000 in 1% BSA in PBS was added for 2 hr at 4OC. Following washing, bound p53 was visualized with 50 ~1 of TMB substrate per well. The color reaction was stopped by the addition of 50 ~1 of 1 M H2S04 per well and the optical density at 450 nm measured. The murine p53 ELISA was standardized by including known quantities of recombinant murine p53 expressed in E. coli and resolubilized from inclusion bodies. fresh medium was added to the cell cultures, and they were incubated 24 hr before being fixed and assayed for LacZ expression with X-Gal. tion of the specific DNA binding function of ~53. Cell 77, 675-888.
